000141513 001__ 141513
000141513 005__ 20240321220952.0
000141513 0247_ $$2doi$$a10.3233/JPD-191672
000141513 0247_ $$2pmid$$apmid:31381528
000141513 0247_ $$2ISSN$$a1877-7171
000141513 0247_ $$2ISSN$$a1877-718X
000141513 0247_ $$2altmetric$$aaltmetric:64772597
000141513 037__ $$aDZNE-2020-07837
000141513 041__ $$aEnglish
000141513 082__ $$a610
000141513 1001_ $$0P:(DE-2719)2813524$$aLöhle, Matthias$$b0$$eFirst author$$udzne
000141513 245__ $$aPutaminal Dopamine Turnover in de novo Parkinson's Disease Predicts Later Neuropsychiatric Fluctuations but Not Other Major Health Outcomes.
000141513 260__ $$aAmsterdam$$bIOS Press$$c2019
000141513 264_1 $$2Crossref$$3print$$bIOS Press$$c2019-10-11
000141513 3367_ $$2DRIVER$$aarticle
000141513 3367_ $$2DataCite$$aOutput Types/Journal article
000141513 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1708347608_1851
000141513 3367_ $$2BibTeX$$aARTICLE
000141513 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141513 3367_ $$00$$2EndNote$$aJournal Article
000141513 520__ $$aTo investigate the predictive value of striatal dopamine turnover in patients with de novo Parkinson's disease (PD) for later occurrence of major non-motor health outcomes.This retrospective, observer-blinded cohort study followed up 29 patients with de novo PD for a median of 10.7 years, who completed 18Fluorodopa PET imaging to measure striatal effective distribution volume ratio (EDVR, inverse of dopamine turnover) prior to antiparkinsonian treatment. Outcomes were assessed with a battery of non-motor, health-related quality-of-life and non-motor fluctuation (WOQ-19) measures and survival.During follow-up, 52% of patients developed wearing-off, 43% neuropsychiatric fluctuations, 35% sensory fluctuations, 32% dementia, 46% depression, 30% psychosis, and PD-related mortality was 26%. Patients with wearing-off and neuropsychiatric fluctuations showed significantly lower baseline EDVR (higher dopamine turnover) in the putamen but not in the caudate nucleus than those without these fluctuations. Consistently, baseline EDVR in the putamen predicted development of wearing-off and neuropsychiatric fluctuations with a lower risk with higher EDVR (lower dopamine turnover), whereas EDVR in caudate nucleus did not correlate with these fluctuations. No relationships were observed between baseline PET measures and the presence of other major health outcomes including survival.Lower putaminal dopamine turnover in de novo PD is associated with reduced risk for later neuropsychiatric fluctuations comprising a disease-intrinsic predisposing factor for their development, similar as reported for levodopa-induced motor complications. Striatal (putaminal/caudate) dopamine turnover is not predictive for other long-term major health outcomes. These results should be treated as hypothesis generating and require confirmation.
000141513 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000141513 588__ $$aDataset connected to CrossRef, PubMed,
000141513 650_2 $$2MeSH$$aAged
000141513 650_2 $$2MeSH$$aCaudate Nucleus: diagnostic imaging
000141513 650_2 $$2MeSH$$aCaudate Nucleus: metabolism
000141513 650_2 $$2MeSH$$aDopamine: metabolism
000141513 650_2 $$2MeSH$$aFemale
000141513 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000141513 650_2 $$2MeSH$$aHumans
000141513 650_2 $$2MeSH$$aMale
000141513 650_2 $$2MeSH$$aNeuropsychological Tests
000141513 650_2 $$2MeSH$$aParkinson Disease: diagnostic imaging
000141513 650_2 $$2MeSH$$aParkinson Disease: metabolism
000141513 650_2 $$2MeSH$$aParkinson Disease: psychology
000141513 650_2 $$2MeSH$$aPositron-Emission Tomography
000141513 650_2 $$2MeSH$$aPutamen: diagnostic imaging
000141513 650_2 $$2MeSH$$aPutamen: metabolism
000141513 650_2 $$2MeSH$$aQuality of Life
000141513 650_2 $$2MeSH$$aRetrospective Studies
000141513 7001_ $$0P:(DE-2719)2814194$$aHermann, Wiebke$$b1$$udzne
000141513 7001_ $$aHausbrand, Denise$$b2
000141513 7001_ $$aWolz, Martin$$b3
000141513 7001_ $$aMende, Julia$$b4
000141513 7001_ $$0P:(DE-HGF)0$$aBeuthien-Baumann, Bettina$$b5
000141513 7001_ $$aOehme, Liane$$b6
000141513 7001_ $$0P:(DE-HGF)0$$avan den Hoff, Jörg$$b7
000141513 7001_ $$aKotzerke, Jörg$$b8
000141513 7001_ $$aReichmann, Heinz$$b9
000141513 7001_ $$0P:(DE-2719)2811732$$aHermann, Andreas$$b10$$udzne
000141513 7001_ $$0P:(DE-2719)9000306$$aStorch, Alexander$$b11$$eLast author$$udzne
000141513 77318 $$2Crossref$$3journal-article$$a10.3233/jpd-191672$$b : IOS Press, 2019-10-11$$n4$$p693-704$$tJournal of Parkinson's Disease$$v9$$x1877-7171$$y2019
000141513 773__ $$0PERI:(DE-600)2599550-9$$a10.3233/JPD-191672$$gVol. 9, no. 4, p. 693 - 704$$n4$$p693-704$$q9:4<693 - 704$$tJournal of Parkinson's Disease$$v9$$x1877-7171$$y2019
000141513 8564_ $$uhttps://pub.dzne.de/record/141513/files/DZNE-2020-07837_Restricted.pdf
000141513 8564_ $$uhttps://pub.dzne.de/record/141513/files/DZNE-2020-07837_Restricted.pdf?subformat=pdfa$$xpdfa
000141513 909CO $$ooai:pub.dzne.de:141513$$pVDB
000141513 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2813524$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000141513 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814194$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000141513 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000141513 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000306$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000141513 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000141513 9141_ $$y2019
000141513 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000141513 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000141513 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000141513 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000141513 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PARKINSON DIS : 2021$$d2022-11-25
000141513 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-25
000141513 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-25
000141513 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ PARKINSON DIS : 2021$$d2022-11-25
000141513 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x0
000141513 9201_ $$0I:(DE-2719)5000014$$kAG Storch$$lNon-Motor Symptoms in Parkinson's disease$$x1
000141513 980__ $$ajournal
000141513 980__ $$aVDB
000141513 980__ $$aI:(DE-2719)1510100
000141513 980__ $$aI:(DE-2719)5000014
000141513 980__ $$aUNRESTRICTED
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/nrneurol.2012.126$$o10.1038/nrneurol.2012.126
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.25157$$o10.1002/mds.25157
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.parkreldis.2018.05.008$$o10.1016/j.parkreldis.2018.05.008
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.parkreldis.2017.06.013$$o10.1016/j.parkreldis.2017.06.013
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.parkreldis.2014.05.010$$o10.1016/j.parkreldis.2014.05.010
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4$$o10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/brain/awl028$$o10.1093/brain/awl028
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0b013e3182918c2d$$o10.1212/WNL.0b013e3182918c2d
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.27466$$o10.1002/mds.27466
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0000000000002286$$o10.1212/WNL.0000000000002286
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00702-006-0554-y$$o10.1007/s00702-006-0554-y
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.parkreldis.2014.11.002$$o10.1016/j.parkreldis.2014.11.002
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.21944$$o10.1002/mds.21944
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.23875$$o10.1002/mds.23875
000141513 999C5 $$2Crossref$$oMantese 2018$$y2018
000141513 999C5 $$2Crossref$$oFahn Recent developments in Parkinson’s disease. 1987$$tRecent developments in Parkinson’s disease.$$y1987
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00415-014-7299-6$$o10.1007/s00415-014-7299-6
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.21333$$o10.1002/mds.21333
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.20844$$o10.1002/mds.20844
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.10656$$o10.1002/mds.10656
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0b013e3181c34b47$$o10.1212/WNL.0b013e3181c34b47
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.parkreldis.2012.08.004$$o10.1016/j.parkreldis.2012.08.004
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.23429$$o10.1002/mds.23429
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-011-1819-8$$o10.1007/s00259-011-1819-8
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.25364$$o10.1002/mds.25364
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.25319$$o10.1002/mds.25319
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0000000000000385$$o10.1212/WNL.0000000000000385
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.26731$$o10.1002/mds.26731
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0b013e318285c0ed$$o10.1212/WNL.0b013e318285c0ed
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/jnnp-2017-316213$$o10.1136/jnnp-2017-316213
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/ana.21204$$o10.1002/ana.21204
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/jnnp.49.10.1182$$o10.1136/jnnp.49.10.1182
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3233/JPD-160996$$o10.3233/JPD-160996
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1093/brain/119.6.2121$$o10.1093/brain/119.6.2121
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.27190$$o10.1002/mds.27190
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1474-4422(16)30328-3$$o10.1016/S1474-4422(16)30328-3
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0000000000003810$$o10.1212/WNL.0000000000003810
000141513 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000341998$$o10.1159/000341998